Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Immunology

Internal Medicine

Endocrinology

Ophthalmology

Show all topics

DOI

10.1016/s0140-6736(22)00018-6

Other Formats

PDF